Download FREE Sample
The Vaccines Market encompasses the research, development, production, and distribution of vaccines, which are biological preparations that stimulate an individual-s immune system to provide immunity against specific diseases. These products include preventive vaccines administered across pediatric, adult, and geriatric populations, as well as emerging therapeutic vaccines targeting chronic and infectious diseases. These vaccines are crucial in preventing infectious diseases and reducing mortality rates worldwide. These vaccines are derived from attenuated or inactivated organisms, recombinant proteins, or newer platforms such as mRNA and viral vectors. The market includes vaccines targeting viral, bacterial, and parasitic infections, administered through government immunization programs, private healthcare providers, and non-profit organizations.
Rising global demand: Addressing the surge in infectious diseases
The increasing global incidence of infectious diseases remains a central factor supporting expansion in the vaccines market. Rising concerns around conditions such as COVID-19, seasonal influenza, hepatitis, and human papillomavirus (HPV) have reinforced the importance of accessible and effective immunization. Health authorities and governments continue to prioritize vaccination programs to limit disease spread, reduce the economic burden of treatment, and improve population-level health outcomes. In addition to individual protection, vaccines play a crucial role in establishing broader community immunity, encouraging wider uptake across different demographic groups. The surge in infectious disease awareness has further accelerated vaccination acceptance, particularly with the growing need for booster doses and targeted immunization strategies for adults and international travellers.
Beyond disease prevalence, the expansion of national immunization programs in emerging economies has strengthened baseline demand, with governments allocating higher healthcare spending toward preventive care and incorporating newer vaccines into routine schedules. Population growth and urbanization patterns are further contributing to the need for structured immunization strategies, particularly in densely populated regions. This trend is especially prominent in rapidly developing regions such as Asia-Pacific, where improving healthcare access and awareness are supporting higher vaccination coverage across diverse population groups. The awareness generated by recurring outbreaks and pandemic events continues to reinforce vaccination as a key component of healthcare systems globally. Additionally, ongoing efforts to control vaccine-preventable diseases are increasingly aligned with global initiatives to address antimicrobial resistance, reinforcing the long-term importance of immunization in reducing dependence on antibiotic treatments and supporting sustained market growth.
To learn more about this report, download the PDF brochure
Transformative innovation: Advancements in mRNA vaccine technology
Advancements in mRNA vaccine technology are reshaping the vaccine landscape by enabling faster and more adaptable development processes, moving from a reactive, long-cycle process to a highly adaptive, rapid-response model. This approach uses genetic instructions to stimulate internal immune responses, allowing vaccines to be designed and produced with greater speed compared to traditional methods, as demonstrated by the rapid development of COVID-19 vaccines, which reached large-scale deployment within an unprecedented timeframe. This success has acted as a catalyst, shifting research focus toward long-term applications in infectious diseases, oncology, and personalized therapeutics.
Beyond COVID-19, progress in platform technologies, including mRNA, DNA-based systems, and viral vectors, has introduced greater flexibility in antigen design. Modern manufacturing, using continuous flow technologies and AI-integrated design, now offers increased scalability and significantly reduced costs. These innovations are supporting the development of combination vaccines and expanding research into applications beyond infectious diseases, including oncology and other therapeutic areas. As research pipelines evolve, these technologies are expected to support more targeted and efficient vaccine solutions, contributing to ongoing shifts in how vaccines are developed and utilized.
To learn more about this report, download the PDF brochure
Vaccine Type Segment Outlook
The global vaccines market is segmented by vaccine type intosubunit vaccines (conjugate/recombinant), mRNA, viral vector, inactivated, and live attenuated vaccines. The conjugate/recombinant vaccine leads the global market due to its strong, long-lasting immunity, especially for pediatric and immunocompromised populations. Further, mRNA vaccines are being recognized for their rapid antigen development; this segment is expected to show the fastest growth rate, driven by COVID-19 and by the potential for cancer/infectious disease applications. Inactivated vaccines represent a mature segment capturing a significant share, commonly used for diseases such as polio, rabies, and hepatitis A, and often utilized in national immunization programs due to high stability. Live attenuated vaccines areused for long-term immunity against diseases like measles, mumps, and ruberal vector vaccines, which gained prominence during the COVID-19 pandemic, remain a key platform utilizing vectors to deliver genetic material.
Regional Outlook: North America to maintains its vaccine market leadership through advanced R&D and robust healthcare infrastructure
North America holds a significant share of the vaccine market, supported by advanced healthcare infrastructure, established immunization programs, and the presence of key market players. Further, rising investments in R&D and the rapid adoption of new vaccine technologies contribute to steady growth in the region. Europe follows closely, with a strong focus on public healthcare systems and coordinated vaccination policies. Moreover, increasing focus on adult immunization and booster programs is further increasing the vaccine demand across the region. The Asia-Pacific region is expected to witness the fastest growth rate in the global vaccine market. The region's growth is driven by rising incidence of infectious diseases, large population bases, and improving healthcare access. Furthermore, advancements in vaccine technology (like mRNA) and government-led immunization initiatives are significantly boosting the region-s growth.
Competitive Landscape Analysis
The global vaccines market is marked by the presence of established and emerging market players such as Merck & Co. Inc. (US); Pfizer Inc. (US); Moderna Inc. (US); CSL Seqirus (AU); Sanofi SA (France); GSK Plc. (UK); Sinovac Biotech Ltd (China); BioNTech SE (Germany); AstraZeneca (UK); Serum Institute of India Pvt. Ltd. (India); and Emergent BioSolutions Inc. (US), among others.
Get a sample report for competitive landscape analysis
Growth strategies adopted by players to establish their foothold in the market
Players operating in this market are adopting various growth strategies such as new product launches and approvals; acquisitions; expansions; and strategic partnerships, agreements, and collaborations, to garner market share. For instance,
- In June 2025, US-based CDMO ProBio opened its flagship 128,000 sq ft GMP facility in Hopewell, New Jersey, to expand plasmid DNA and viral vector manufacturing capacity, supporting clinical development and large-scale production of gene and cell therapies
- In November 2024, SyVento BioTech launched a new mRNA manufacturing facility in Poland, equipped with Cytiva-s FlexFactory platform to support integrated, end-to-end production of mRNA-based therapies from laboratory to commercial scale, enhancing in-region manufacturing capabilities for RNA-based therapeutics
- In May 2024, GenScript launched a self-amplifying RNA synthesis service for advanced therapeutic applications, boosting potency and efficiency for vaccine, immunotherapy, and gene therapy development
- In June 2023, Samsung Biologics and Pfizer announced a strategic partnership for the long-term commercial manufacturing of Pfizer-s multi-product portfolio, under which Samsung Biologics provided additional capacity for the large-scale manufacturing of a biosimilar-s portfolio covering oncology, inflammation, and immunology, using its newest facility, Plant 4
Report Scope
| Report Metric | Details |
|
Base Year Considered |
2025 |
|
Historical Data |
2024 - 2025 |
| Forecast Period |
2026 - 2031 |
| Growth Rate |
7% |
|
Segment Scope |
Vaccine Type, Route of Administration, Disease Type, Age, and Distribution Channel |
|
Regional Scope |
|
|
Market Drivers |
|
|
Attractive Opportunities |
|
|
Key Companies Mapped |
Merck & Co. Inc. (US); Pfizer Inc. (US); Moderna Inc. (US); CLS Seqirus (AU); Sanofi SA (France); GSK Plc. (UK); Sinovac Biotech Ltd (China);BioNTech SE (Germany); AstraZeneca (UK); Serum Institute of India Pvt. Ltd. (India); and Emergent BioSolutions Inc. (US), among others |
|
Report Highlights |
Market Size & Forecast, Growth Drivers & Restraints, Trends, Competitive Analysis |
Global Vaccines Market Segmentation
This report by Medi-Tech Insights provides thesize of the global vaccines market at theregional and country-level from 2024 to 2031. The report further segments the market by vaccine type, route of administration, disease type, age, and distribution channel.
Market Size & Forecast (2024-2031), By Vaccine Type, USD Billion
- Recombinant Vaccines
- Conjugate Vaccines
- Inactivated
- Live Attenuated
- Viral Vector Vaccines
- mRNA Vaccines
- Others
Market Size & Forecast (2024-2031), By Route of Administration, USD Billion
- Oral
- Parenteral
- Nasal
Market Size & Forecast (2024-2031), By Disease Type, USD Billion
- Viral Di>Hepatitis
- Influenza
- HPV
- MMR
- Rotavirus
- Herpes Zoster
- Covid-19
- Others
- Bacterial Vaccines
- Meningococcal Diseases
- Pneumococcal diseases
- DPT
- Others
- Cancer Vaccines
- Allergy Vaccines
- Others
Market Size & Forecast (2024-2031), By Age, USD Billion
- Paediatric
- Adult
Market Size & Forecast (2024-2031), By Distribution Channel, USD Billion
- Hospitals
- Retail Pharmacies
- Government Suppliers
- Others
Market Size & Forecast (2024-2031), By Region, USD Billion
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Rest of Asia Pacific
- Latin America
- Middle East & Africa
Frequently Asked Questions About This Report
What is the market size & forecast of the Vaccines Market?
What are historical, present, and forecasted market shares and growth rates of various segments and sub-segments of the dental regeneration market?
What are the key trends defining the market?
What are the major factors impacting the market?
What are the opportunities prevailing in the market?
Need a More Tailored Analysis?
- Discuss the market sizing methodology and forecast assumptions with our healthcare analysts.
- Expand the scope with additional countries, market segments, technologies, or competitor profiling.
- Use the insights to support strategic planning, market entry, commercial due diligence, and long-term revenue growth initiatives.
